Articles tagged with: Multiple Myeloma Research Consortium
News »
Fred Hutchinson Cancer Center To Field Questions At The Beacon’s Forums This Week – Dr. William Bensinger, myeloma expert at the Fred Hutchinson Cancer Center in Seattle, WA, will be be responding to medical questions posted in the Myeloma Beacon’s forums this week. Readers who have not yet visited the Beacon’s new myeloma discussion forums are encouraged to do so, as they already contain a number of informative postings about topics such as myeloma treatment options, managing treatment side effects, and alternative myeloma therapies.
Treanda Combination Therapy Enters Phase 1B/2 Trial For Multiple Myeloma – Last week, the Multiple Myeloma Research Consortium (MMRC) announced the start of a Phase 1B/2 clinical trial that will evaluate a combination of Treanda (bendamustine), Revlimid (lenalidomide) and dexamethasone (Decadron) in relapsed multiple myeloma patients. Treanda is already approved in Germany in combination with prednisone for the treatment of multiple myeloma. In the United States, the drug is approved for the treatment of chronic lymphocytic leukemia and certain lymphomas. For more information, see the MMRC press release or the clinical trial description.
MMRF Kicks Off Race For Research 5K Walk/Run Series – On April 25, the Multiple Myeloma Research Foundation (MMRF) will kick off its annual Race For Research 5K Walk/Run series to raise awareness and funds for multiple myeloma research. The events will take place in eight cities across the Unites States. The first one is scheduled for April 25 in San Francisco. For more information and registration details, see the MMRF Web site.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
Headline, News »
Preliminary results from an ongoing Phase 1 clinical trial indicate that carfilzomib, a new proteasome inhibitor, has significant therapeutic results in patients with relapsed myeloma. The Multiple Myeloma Research Consortium (MMRC) reported the results at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, which was held in Berlin from September 20 to 24.
Carfilzomib selectively induces cell death in cancer cells by blocking the activity of proteasomes, which are enzymes that break down proteins. Carfilzomib is similar to Velcade (bortezomib), the first proteasome inhibitor approved for multiple myeloma treatment.…
Headline, News »
For the first time, researchers have sequenced the full multiple myeloma genome.
Sequencing the full multiple myeloma genome enables scientists to discover which genes are present in a myeloma tumor, as well as to determine which genetic regions may harbor mutations. This knowledge will help researchers better understand both myeloma’s development — how normal plasma cells in the bone marrow transform into cancerous ones – and new, tailored targets for attacking the disease.
This genetic reconstruction project by the Multiple Myeloma Genomics Initiative, which is spearheaded by the Multiple Myeloma…